Sutro Biopharma(STRO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., May 8, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2025 and recent business highlights. • In March, Sutro announced completion of a strategic portfolio review resulting in the prioritization of its wholly ...